Bio-Techne Corp (TECH) Stock Price & Analysis
Bio-Techne Corp (TECH) rose 3.34% to USD 54.41 as of June 10, 2026 at 00:53 UTC, according to Nexqual real-time market data.
TECH last closed at USD 52.65; the session ranged USD 53.17–55.12 on volume of 3,529,139 shares. Market capitalization is $8.52B, with a 52-week range of USD 43.2–72.16 (NMS). Source: Nexqual, June 10, 2026 at 00:53 UTC.
Key Statistics (as of June 10, 2026 at 00:53 UTC)
| Price | USD 54.41 |
|---|---|
| Change | ▲ 3.34% (up) |
| Previous Close | USD 52.65 |
| Open | USD 53.44 |
| Day Range | USD 53.17 – 55.12 |
| 52-Week Range | USD 43.2 – 72.16 |
| Volume | 3,529,139 shares |
| Market Cap | $8.52B |
| Exchange | NMS |
Technical Analysis (TECH)
Nexqual's technical model rates TECH "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:53 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.39 (neutral) |
| vs SMA50 | Above (USD 52.25) |
| MACD | 0.46 (positive) |
Analyst Ratings (TECH)
Wall Street analysts rate TECH "Buy" based on 12 analysts, with a mean price target of USD 61.42 (range USD 49–75), per Nexqual as of June 10, 2026 at 00:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 61.42 |
| High Target | USD 75 |
| Low Target | USD 49 |
| Buy / Hold / Sell | 10 / 5 / 0 |
Earnings (TECH)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.52 |
| Revenue Estimate | $314.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.53 vs est 0.53 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.43 ▲ beat |
| 2025-09-30 | USD 0.42 vs est 0.42 ▼ miss |
| 2025-06-30 | USD 0.53 vs est 0.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financials & Fundamentals (TECH)
| Total Revenue | $1.21B |
|---|---|
| Revenue Growth (YoY) | -1.50% |
| Gross Margin | +66.40% |
| Operating Margin | +25.19% |
| Profit Margin | +9.05% |
| ROE | +5.34% |
| Debt / Equity | 13.92 |
| Current Ratio | 4.49 |
| Total Cash | $214.11M |
| Total Debt | $290.32M |
| Free Cash Flow | $299.85M |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Financial Health Score (TECH)
Nexqual rates Bio-Techne Corp's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:53 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 25% |
| Balance Sheet | Strong — $214M cash vs $290M debt |
| Cash Flow | Strong — FCF $300M, 25% margin |
| Efficiency | Mixed — ROE 5%, ROA 7.5% |
Ownership (TECH)
| Insider Ownership | +0.31% |
|---|---|
| Institutional Ownership | +117.91% |
| Shares Outstanding | 156.57M |
| Float | 155.97M |
| Short % of Float | +10.09% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
Leadership (TECH)
Bio-Techne Corp is led by Kim Kelderman (age 57), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:53 UTC.
| CEO, President & Director | Kim Kelderman (age 57) |
|---|---|
| Executive VP of Finance & CFO | James T. Hippel (age 54) |
| President of Protein Sciences Segment | William A. Geist (age 56) |
| VP & CTO | Gary J. Latham |
| Vice President of Sales and Marketing | Gerry Andros |
Major Backers & Investors (TECH)
Notable institutional backers of Bio-Techne Corp include Morgan Stanley, FMR, LLC, Invesco, according to Nexqual as of June 10, 2026 at 00:53 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 5.45% |
| FMR, LLC | 5.05% |
| Invesco | 4.94% |
| Wellington Management | 3.27% |
| Maverick Capital Ltd. | 3.03% |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.85% |
| BlackRock | 9.12% |
| State Street | 3.75% |
| Geode Capital | 3.27% |
Source: Nexqual, June 10, 2026 at 00:53 UTC.
From Bio-Techne Corp's Latest SEC 10-K Filing (filed 2025-08-22)
Key Strengths & Strategy (as disclosed to the SEC)
- Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
- The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
- The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
- This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
| BIO | Bio-Rad Laboratories, Inc. | USD 297.17 | ▲ 0.97% |
| TFX | Teleflex Incorporated | USD 135.75 | ▲ 4.55% |
| STE | STERIS plc (Ireland) | USD 212.88 | ▲ 0.25% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:53 UTC. This page is informational and not investment advice.